Evidence map›Paper›PMID 40752997›Full record

ArticleTrends in pharmacological sciences2025

Beyond G protein and arrestin: GRK2-biased β₂AR signaling.

Ren-Lei Ji, Zhe Wang, Jean J Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Trends in pharmacological sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ren-Lei JiDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02215, USA.
Zhe WangDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Jean J ZhaoDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02215, USA. Electronic address: jean_zhao@dfci.harvard.edu.

Funding

Tissue and Pathology CoreP50CA168504 · NCI · DANA-FARBER CANCER INST · PI LEIF W ELLISEN, NANCY U LIN · 2013 to 2026
$30.1M
Targeting WEE1 in uterine serous or p53-mutated uterine cancerP01CA269021 · NCI · DANA-FARBER CANCER INST · PI Panagiotis Konstantinopoulos, Joyce Liu · 2024 to 2026
$11.8M
Integrating targeted therapy and immunotherapy to break through cancerR35CA210057 · NCI · DANA-FARBER CANCER INST · PI Jean Zhao · 2016 to 2026
$10.8M
NCI NIH HHS P01 CA269021NCI NIH HHS P50 CA168504NCI NIH HHS R35 CA210057
6 · The paper itself

Abstract

Biased G-protein-coupled receptor (GPCR) signaling is reshaping drug discovery by enabling pathway-selective drug action. Recent work by Motso et al. identified GPCR kinase 2 (GRK2) as a non-canonical transducer, independent of G proteins or β-arrestins, redefining the biased signaling landscape and highlighting GRK2 as a novel therapeutic target for selective modulation of GPCR-driven metabolic responses.

Indexed as

G-Protein-Coupled Receptor Kinase 2Receptors, Adrenergic, beta-2AnimalsGTP-Binding ProteinsHumansSignal TransductionG-Protein-Coupled Receptor Kinase 2GRK2 protein, humanGTP-Binding ProteinsReceptors, Adrenergic, beta-2biased agonismdiabetesprecision pharmacology

Identifiers

PMID40752997
PMCPMC12321243

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.